Renfeng Guo
Gründer bei INFLARX N.V.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Renfeng Guo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INFLARX N.V. | Direktor/Vorstandsmitglied | 01.12.2007 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.12.2007 | - | |
| Gründer | 01.12.2007 | - |
Karriereverlauf von Renfeng Guo
Ehemalige bekannte Positionen von Renfeng Guo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of Michigan | Corporate Officer/Principal | 01.01.2001 | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Direktor/Vorstandsmitglied | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | 11.12.2007 | - | |
| Gründer | 25.11.2009 | - |
Ausbildung von Renfeng Guo
| Norman Bethune Medical University | Doctorate Degree |
Statistik
International
| Deutschland | 3 |
| China | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Börse
- Insiders
- Renfeng Guo
- Erfahrung
